Introduction: 'Real-world evidence (RWE)' refers to information on the utilization and outcome of new therapies and technologies in clinical practice. RWE may include single institution cohort studies, population-based health services studies, or (inter)national data on survival and mortality. This paper reviews RWE on the impact of treatment in ovarian cancer.
Introduction
Randomized clinical trial (RCT) evidence leads to regulatory approval and incorporation of novel treatments and technologies into practice. 'Real-world evidence' (RWE) refers to information on the utilization and outcome of new therapies and technologies in clinical practice. RWE is a broad term that may include data from single institution cohort studies, population-based health services and observational research, and (inter)national data on survival and mortality. Such studies can provide information about the uptake of new treatments, their safety and effectiveness in clinical practice and/or explore trends in overall outcomes between groups of patients or points in time.
As the costs of new cancer interventions have risen, and the bar for their marketing approval has fallen, there has been increasing attention paid to whether such new therapeutics 'deliver' improved outcomes (effectiveness) without unexpected toxicity in the real world of practice. Such information may affect ongoing reimbursement and illuminate the benefits of treatments in the more generalized populations to which new therapies may be applied. For example, clinical trials may restrict patient entry to those with good performance status and no brain metastases while in practice, a broader range of patients will be treated. Understanding the outcomes in the 'real-world' population treated provides valuable additional information to practitioners, patients and policy makers.
RWE also examines different patterns of care within populations by geography or over time and may be used to make inferences about the impact of those care patterns on patient and disease outcomes-helping to drive policy or guideline change when RCTs are not feasible. For example, the work of Booth et al. in demonstrating a population level impact of perioperative chemotherapy (neoadjuvant and adjuvant) in muscle invasive bladder cancer in Ontario has led to a renewed discussion on the place of adjuvant chemotherapy in this patient group [1] .
It is important to understand the strengths/weaknesses of RWE in interpreting results of such studies: when comparisons are made in particular, it is important to note that biases are inevitable using RWE-particularly when contemporaneous treatments are compared in a single institution because patients are selected to undergo different treatments and systematic bias may be introduced. More weight may be given to populationbased datasets with comparisons before/after a critical date (e.g. when a new drug or technique becomes available) or between jurisdictions/centers and in examining trends over time. A recent review of comparing population-based observational studies and randomized controlled trials outlines the strengths and weaknesses of each, and illustrates the complementary features they bring to bear on the evolution of medical evidence in practice [2] .
In seeking to identify the impact of new ovarian cancer treatments on population outcomes, it is important to appreciate the time points at which major new therapeutic or potential prevention approaches have been introduced over the last four decades. Figure 1 summarizes these graphically.
In this paper, evidence of improved population outcomes from ovarian cancer treatment was studied by seeking publications that evaluated RWE of benefit of specific new treatments. These were, however, rare. Some of those identified in a literature review are summarized below. Thus the question of the effects of treatment over time was also investigated by examining trends in ovarian cancer population mortality and incidence, as a means of exploring the net impact of treatment on outcomes.
RWE studies of neoadjuvant chemotherapy (NACT) followed by debulking surgery versus primary debulking surgery.
The practice of NACT has risen since the publication of the EORTC [3] and CHORUS [4] randomized trials that concluded NACT was 'non-inferior' to standard primary debulking strategy in management of patients 'who were fit for either procedure'. Furthermore, the trial data suggested that surgical morbidity was lower in the NACT group. But controversy remains about the effectiveness of adopting this approach in practice, largely fueled by concerns about the reported survival in the two RCTs, the long history of primary debulking surgical practice and some smaller cohort studies suggesting worse outcomes in patients selected to receive NACT versus primary debulking [5] . Since patients in cohort analyses are not randomly assigned-and since those with adverse prognostic indicators (e.g. poor performance status, greater disease burden, comorbidities) may be preferentially offered NACT [see for example the criteria of the American Society of Clinical Oncology (ASCO) guideline [6] : 'Women who have a high perioperative risk profile or a low likelihood of achieving cytoreduction to 1 cm (ideally to no visible disease) should receive NACT'], it is to be expected that without careful correction for those factors, NACT outcomes will appear worse.
One recent large study has attempted to address these shortcomings by undertaking a propensity score matched analysis of NACT outcomes in a population dataset. The study by RauhHain et al. used the US National Cancer Database and compared the outcomes of 2935 patients planned to receive NACT followed by surgery with 2935 patients planned to receive primary debulking followed by chemotherapy matched for age, stage, grade and histology [7] . Interestingly, in the NACT group, only 74% received surgery and in the primary debulking group, only 85% received post-op chemo. Median survival was shorter for NACT patients (32.1 versus 37.3 months) but the authors also showed that a fairly minor maldistribution of performance status 1-2 (not matched for in the data) of 60% in NACT and 50% in upfront surgery groups would have obscured the survival difference. This type of study underscores the complexity of using RWE to draw comparisons when 'non-random prognostic associated factors lead to differential treatment assignment'.
One of the great controversies in the field of ovarian cancer treatment is that surrounding the use of intravenous (i.v.)/intraperitoneal (i.p.) chemotherapy in patients with optimally debulked ovarian cancer. Three RCTs have shown 'superiority' in overall survival with i.v./i.p. treatment, yet each was greeted with criticism regarding the design, the treatment and control arm composition and thus also skepticism with respect to the trials' conclusions. These factors, coupled with concern over toxicity and the inconvenience of i.p. administration, have led to limited uptake of i.v./i.p. treatment in many regions. A recent 'real-world' study documented the changing trends of use of i.v./i.p. treatment in some centers in the United States, and also described the impact on outcomes [8] . group. These data are supportive of the earlier clinical trials findings but also could not be controlled for all the variables that may have led to the selection of one treatment over the other. On the other hand, in this example, the use of i.v./i.p. treatment was largely determined by 'policy change' at a specific time point rather than individual patient characteristics, since its uptake increased over time. Another interesting analysis would have been to compare the outcomes in the two time periods (before/after i.v./i.p. uptake), regardless of treatment assigned.
Inferences about the real-world impact of treatment-trends in survival and mortality rates
The goal of prevention, early diagnosis/screening and treatment of cancer is to reduce incidence rates and improve survival and mortality rates (the burden of disease) in the population. The cumulative impact of new treatments should, therefore, be reflected in improved population survival rates and reduced mortality from disease.
Changes in population 'survival rates' (changes over time in the likelihood of surviving a diagnosis of cancer) are complex to use for this purpose since they may be influenced by lead time bias (trends to earlier diagnosis through screening programs or greater awareness of early disease, for example, may give the impression of longer survival) and corrections must take place to ensure deaths from other causes are not incorrectly attributed to malignant disease (often through use of net/relative survival or cancer specific survival measures).
'Mortality rate' (deaths per 100 000 age-standardized population) is a complementary approach to investigate if treatments are having a desirable effect, but it is important to note that agestandardized mortality rates are also subject to the influence of factors other than treatment, notably changes in 'incidence rates'. While not all interventions that cause an increase in incidence rate lead to a rise in mortality rate, some do. On the other hand, in general, factors/interventions leading to decline in incidence rates normally lead to a decline in mortality rates. The most convincing evidence of the impact of treatment comes when incidence rates remain unchanged yet mortality rates fall. Table 1 outlines the potential interactions between interventions affecting treatment and incidence on survival and mortality statistics. Decrease Impact on mortality rates depends on degree of reduction (e.g. HPB vaccination in hepatocellular ca) Risk factor increase Increase Increase e.g. tobacco smoking increase (or decrease) with parallel effects on incidence and mortality Effective (curative) treatment
No effect Decrease Impact depends on magnitude of effect and proportion of population affected (e.g. adjuvant breast cancer treatment; systemic chemotherapy for testicular Ca)
Ovarian cancer incidence, mortality and survival trends
What can be inferred about 'real-world' effectiveness of ovarian cancer treatments (surgery, chemotherapy, etc.) through mortality trends? The situation is complicated because over the last three decades incidence rates have been falling. Some of this fall is attributed to the widespread use of protective oral contraceptive drugs [9] and of decreased use of postmenopausal hormone supplementation [10] . Not surprisingly, mortality rates have also been falling. One approach to assess the impact of treatment on mortality, over and above that of change in incidence, is to evaluate whether mortality rates have been falling 'to a greater degree' than incidence rates. Some data suggests that this may be the case.
In the United States, modeling of SEER data show that 2004-2013 incidence rates for new ovarian cancer cases have been falling on average 1.9% each year over the last 10 years. Mortality rates have been falling on average 2.2% each year over this same period [11] . Looking further back (1975-2013) incidence rates have fallen between 1975 and 2014 from 16.3 to 11.4 per 100 000 and death rates from 9.8 to 7.02 per 100 000. Over a similar period , relative 5-year survival has increased from 33.7% to 46.2% [11] .
In France between 1980 and 2012, incidence rates have fallen by 0.6% per year and mortality rates by 1.2% per year [12] . This observation mirrors trends in ovarian cancer mortality rates across other European countries and globally. A recent report shows an overall decline in mortality rates from 2002 to 2012 with an EU mortality rate of 5.2 per 100 000 in 2012 [13] . The degree of fall and the absolute mortality rate varies across EU countries and others across the globe. The authors attribute the majority of the decline in mortality to changes in incidence rates through oral contraceptive use and, beginning about 10 years ago, declines in menopausal hormone use, as previously noted [9, 10] . In their view, the impact of treatment was not as substantial as changes in incidence rates which were believed to play the major role in the fall in mortality.
Population data such as these are complex to analyze-and the relative impact of changes in incidence rates (which have been notable) and the effects of treatment are difficult to disentangle. Nonetheless, the data are 'consistent' with an impact of treatment on mortality rates-though perhaps less marked than that of falling incidence rates.
Conclusions
Real-world data on treatment impact is important to document since the goal of clinical research (and its uptake into practice) is to reduce the overall burden of disease. Prospective and retrospective cohort data as well as population level data can illuminate the degree of uptake of new treatments and provide supplemental information on their safety and effectiveness. Comparative analyses are challenging since non-randomized comparisons carry inherent biases. Trends in outcomes over time may also offer evidence of the impact of new treatments, though these analyses also have limitations. Some have suggested that prospective assessment of RWE should be built into the reimbursement process for new drugs, especially those of high cost and marginal benefit, with their continued approval being conditional upon observations of supporting safety and effectiveness within the population for which they are prescribed in practice.
With respect to RWE of treatment impact in ovarian cancer, in this review some examples of population and cohort studies evaluating the uptake and outcomes of new treatments in ovarian cancer were highlighted. Such studies were infrequent, however, thus mortality as well as survival data were reviewed in an attempt to ascertain the impact of three decades of new treatments on ovarian cancer outcomes. Ovarian cancer 5-year relative survival rates are increasing (the example from SEER data are cited), and, in the absence of a substantial stage shift phenomenon (which is unlikely given no population screening programs are in use), this is most plausibly related to improved treatment effects. Mortality rates are also falling, but the interpretation of these data is made difficult by the fact that incidence rates are also declining. RWE including population-based studies will never replace randomized clinical trials-but they offer complementary information for practitioners, patients and policy makers and are thus 'partners in the evolution of medical science' [2] . More such studies in ovarian cancer are needed.
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